The Health Care M&A Report tallies Q1 2014 deal volume of 239 transactions valued at $49.6B. The number of deals for Q4 2013 and Q1 2013 were 278 and 212, respectively. The $49.6B total value was up 11% versus Q4 and up 217% versus Q1.
The most deals were consummated in long-term care (60), pharmaceuticals (33), biotech (26) and devices (25).
Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity. Dec. 14, 2011, 7:50 AM